Rocked by allegations, Novena Global Healthcare board takes over running of firm from Loh cousins
Sinopharm Capital among investors guarding their interests over the company's accounts
Singapore
A GROUP of chafed investors in Novena Global Healthcare Group (NGHG) is moving to guard its interests on concerns about the company's accounts. Among these investors: Sinopharm Capital, the private equity arm of Chinese pharmaceutical giant Sinopharm.
On Friday, NGHG's board shot out a statement that it was "deeply concerned" by recent developments, and has set up a special committee to investigate allegations that the audit signatures on the firm's accounts were forged and to "restructure and scrutinise" its affairs.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Wynn Resorts quarterly results beat estimates on strength in Macau business
Gold prices hold ground as traders eye US Fed cues
Amazon’s AWS puts another S$12 billion into its Singapore cloud infrastructure
UG Healthcare fully acquires German subsidiary for 16.9 million euros
SGX securities turnover jumps 37% in April; derivatives activity continues to gain ground
Singapore shares dip at Wednesday’s open; STI down 0.4%